Literature DB >> 22730526

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.

Raphael Itzykson, Sylvain Thépot, Bruno Quesnel, Francois Dreyfus, Christian Recher, Eric Wattel, Claude Gardin, Lionel Adès, Pierre Fenaux.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22730526     DOI： 10.1182/blood-2012-04-422204

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

Review 1.  Predicting response to epigenetic therapy.

Authors:  Marianne B Treppendahl; Lasse S Kristensen; Kirsten Grønbæk
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 2.  Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).

Authors:  Ehab Atallah; Kathryn Bylow; Jesse Troy; Wael Saber
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

Review 3.  Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Mohamed A Kharfan-Dabaja; Rami S Komrokji
Journal:  Curr Opin Hematol       Date:  2014-03       Impact factor: 3.284

4.  Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

Authors:  A M Zeidan; M A Sekeres; G Garcia-Manero; D P Steensma; K Zell; J Barnard; N A Ali; C Zimmerman; G Roboz; A DeZern; A Nazha; E Jabbour; H Kantarjian; S D Gore; J P Maciejewski; A List; R Komrokji
Journal:  Leukemia       Date:  2015-10-14       Impact factor: 11.528

Review 5.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

Review 6.  Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

Authors:  Daniel A Roberts; David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

7.  Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Ju-Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R Smith; Elisabeth Paietta; Janice Gabrilove; Harry P Erba; Martin S Tallman; Steven D Gore
Journal:  Br J Haematol       Date:  2014-04-09       Impact factor: 6.998

8.  Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Authors:  Amer M Zeidan; Ju-Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R Smith; Elisabeth Paietta; Janice Gabrilove; Harry P Erba; Rhett P Katterling; Martin S Tallman; Steven D Gore
Journal:  Br J Haematol       Date:  2014-07-04       Impact factor: 6.998

Review 9.  Decision Analysis of Transplantation for Patients with Myelodysplasia: "Who Should We Transplant Today?"

Authors:  Shukaib Arslan; Ryotaro Nakamura
Journal:  Curr Hematol Malig Rep       Date:  2020-08       Impact factor: 3.952

10.  Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods.

Authors:  Wael Saber; Jennifer Le Rademacher; Mikkael Sekeres; Brent Logan; Moira Lewis; Adam Mendizabal; Eric Leifer; Frederick R Appelbaum; Mary M Horowitz; Ryotaro Nakamura; Corey S Cutler
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-24       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.